Financial reports
20-F
2022 FY
Annual report (foreign)
10 Apr 23
20-F
2021 FY
Annual report (foreign)
29 Apr 22
20-F
2020 FY
Annual report (foreign)
30 Apr 21
20-F
2019 FY
Annual report (foreign)
30 Apr 20
20-F/A
2018 FY
Annual report (foreign) (amended)
31 Jan 20
20-F/A
2018 FY
Annual report (foreign) (amended)
23 Jan 20
20-F
2018 FY
Annual report (foreign)
30 Apr 19
20-F
2017 FY
Annual report (foreign)
23 Apr 18
20-F
2016 FY
Annual report (foreign)
24 Feb 17
20-F
2015 FY
Annual report (foreign)
29 Mar 16
Current reports
6-K
Report of Foreign Private Issuer
22 Apr 24
6-K
Report of Foreign Private Issuer
16 Apr 24
6-K
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
11 Apr 24
6-K
Report of Foreign Private Issuer
29 Mar 24
6-K
Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method
7 Feb 24
6-K
Report of Foreign Private Issuer
22 Jan 24
6-K
Report of Foreign Private Issuer
17 Jan 24
6-K
Enlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis
20 Dec 23
6-K
Condensed Consolidated Financial Statements
9 Nov 23
6-K
Report of Foreign Private Issuer
7 Nov 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
30 Dec 22
F-3
Shelf registration (foreign)
29 Apr 22
S-8
Registration of securities for employees
4 Jun 21
424B5
Prospectus supplement for primary offering
10 Feb 21
FWP
Free writing prospectus
10 Feb 21
F-3MEF
Registration statement to add securities to prior F-3 registration
9 Feb 21
FWP
Free writing prospectus
9 Feb 21
424B5
Prospectus supplement for primary offering
9 Feb 21
424B5
Prospectus supplement for primary offering
22 Oct 20
424B5
Prospectus supplement for primary offering
3 Mar 20
Proxies
No filings
Other
EFFECT
Notice of effectiveness
6 May 22
CORRESP
Correspondence with SEC
3 May 22
UPLOAD
Letter from SEC
2 May 22
UPLOAD
Letter from SEC
3 Feb 20
CORRESP
Correspondence with SEC
31 Jan 20
UPLOAD
Letter from SEC
27 Jan 20
UPLOAD
Letter from SEC
12 Dec 19
EFFECT
Notice of effectiveness
10 Jul 19
CORRESP
Correspondence with SEC
5 Jul 19
UPLOAD
Letter from SEC
3 Jul 19
Ownership
SC 13G/A
Beneficial ownership report (amended)
14 Feb 20
SC 13G/A
Enlivex Therapeutics Ltd.
9 Sep 19
SC 13G
Enlivex Therapeutics Ltd.
27 Jun 19
SC 13G
Enlivex Therapeutics Ltd.
26 Jun 19
SC 13G
Enlivex Therapeutics Ltd.
26 Jun 19
SC 13G
Enlivex Therapeutics Ltd.
19 Jun 19
SC 13D
Enlivex Therapeutics Ltd.
31 May 19
SC 13G/A
Bioblast Pharma Ltd.
14 Feb 19
SC 13G/A
Bioblast Pharma Ltd.
14 Feb 19
SC 13G/A
Bioblast Pharma Ltd.
14 Feb 18